Cannabis Reference Standards DAB
In the Federal Gazette (Bundesanzeiger) of 23 May 2023, an announcement of the German Federal Institute for Drugs and Medical Devices (BfArM) of 15 May 2023 concerning the German Pharmacopoeia (Deutsches Arzneibuch, DAB) was published. The announcement lists the new and revised DAB texts and monographs adopted by the DAB Commission in October 2022.
Revised Cannabis Reagents
The DAB currently contains the two monographs Cannabis Flower and Cannabis Extract. Reference substances, such as cannabinol (CBN) and cannabidiol (CBD), are required for assay and purity tests, as well as for identity tests (TLC), specified therein. In a previous notice from the BfArM the Expert Committee for Pharmaceutical Biology recommended revised reagent descriptions for inclusion in the DAB.
The DAB 2023 now includes in chapter "N 4 Reagents" the following revised texts for Cannabis reagents:
- Cannabidiol RN
- Cannabidiolic Acid RN
- Cannabinol RN
- Delta-8-Tetrahydrocannabinol RN
- Delta-9-Tetrahydrocannabinol RN
- Delta-9-Tetrahydrocannabinolic Acid RN
The amended German Pharmacopoeia (DAB) is valid from 1 August 2023. The new version is entitled "Deutsches Arzneibuch 2023 (DAB 2023)" and can be obtained from the German publisher "Deutscher Apotheker Verlag".
Related GMP News
10.07.2025New Ph. Eur. Chapter for Estragole Determination
10.07.2025EMA Reflection Paper on Data Recommendations for Herbal Medicinal Products
09.07.2025USP HMC Publishes Final Cannabis Flower Monograph
01.07.2025GMP non-Compliance Reports for two Cannabis Sites
20.05.2025Update on the USP CBD Monograph
20.05.2025Proposed USP Quality Attributes for Cannabis in Clinical Investigations